These contracts, which are with an international biotechnology company, cover regulatory submission services, support of new clinical trials, and changes-of-scope for existing studies. The therapeutic areas covered in these contracts are oncology and rheumatology.
Kenneth Borow, president and CEO of Encorium Group, said: “These trials in oncology and rheumatology focus on developing fully human antibody therapeutics for unmet medical needs. They represent important business opportunities for Encorium with a repeat client.”